Don't know why people are pissed.. I mean, he said it was a 'mistake'.

Are you observing how things are taking shape and being more and more transparent.

If some break the law of national traitorous act and corruption beyond the comprehensive understanding...

What is law if there's no justice.

God fearing Patriotic servant's would not just accept being cheated on by a little group of people who are only useful as puppets, because they will not be able to make a single decision or action without a master to use them.


We were slave to the deep state and their wickedness.

We returned the favor in exchange.

Puppets don't think (because they are stupid) but , the masters pushing and navigating them are. They cannot survive without their masters.

Guess who Q Team removed from the Puppets?

Exactly!

The brilliance of the plan is to make it so tactical and stealthy.. Unnoticeable!

Yet they are being pushed by White Hats into failures and publicly discernment. For the people to see.
The more Qanon is pushed as ridiculous. The more we win. The more they fail.

GUARDS - DOWN 🕵️

(ACTIV-1
Immune Modulators)

The ACTIV-1 master protocol(link is external) will test promising immune modulator compounds, a class of drugs that help minimize the deleterious effects of an overactive immune response to SARS-CoV-2 infection. This Phase 3 trial will enroll hospitalized adults with moderate to severe COVID-19 disease. It will evaluate the safety and efficacy of at least three immune modulators when given as an add-on therapy to remdesivir, an antiviral approved for treatment of COVID-19, and the standard of care in use at local clinics. The different treatments will be assessed with respect to illness severity, recovery speed, mortality and hospital resource utilization.


(ACTIV-2
Outpatient Monoclonal Antibodies and Other Therapies)

The ACTIV-2 master protocol(link is external) is designed as a Phase 2 trial that can expand seamlessly to Phase 3. The trial will enroll adults with COVID-19 who are not hospitalized and aims to evaluate safety, to understand if the investigational treatment can reduce the duration of symptoms, and to test if the treatment can increase the proportion of participants with undetectable virus. It will perform testing using nasopharyngeal swabs at specific time points. Multiple therapies, beginning with a monoclonal antibody but including other types of therapeutics, will be tested in ACTIV-2.


(ACTIV-3
Inpatient Monoclonal Antibodies and Other Therapies)

The ACTIV-3 master protocol(link is external) is designed as a Phase 3 trial with two stages of testing, allowing for quick analysis of compounds for effectiveness in Stage 1 and then a seamless progression to Stage 2 to validate the compound for broader use in patients. The trial will enroll hospitalized adults with COVID-19 and primarily aims to evaluate safety and to understand if the investigational treatment can reduce time to recovery and to understand a treatment’s effect on extrapulmonary complications and respiratory dysfunction. Multiple therapies, beginning with a monoclonal antibody but including other types of therapeutics, will be tested in ACTIV-3.


(ACTIV-4
Antithrombotics)

The ACTIV-4 master protocol will evaluate the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19. Currently there are three adaptive platform clinical trials within ACTIV-4 that aim to prevent, treat, and address COVID-19-associated coagulopathy (CAC), or clotting, as well as help understand the effects of CAC across three patient populations: inpatient, outpatient, and convalescent. The trial infrastructure will also be poised to rapidly test promising new agents. The adaptive nature of the platform will allow a seamless transition to studies that will test multi-regimen anticoagulation approaches.

The ACTIV-4 outpatient protocol(link is external) investigates whether anticoagulants or antithrombotic therapy can reduce life-threatening cardiovascular or pulmonary complications in newly diagnosed COVID-19 patients who do not require hospital admission. Participants will be assigned to take either a placebo, aspirin, or a low or therapeutic dose the blood thinner apixaban.

The ACTIV-4 inpatient protocol (link is external)investigates an approach aimed at preventing clotting events and improving outcomes in hospitalized COVID-19 patients. It will evaluate the safety and effectiveness of using varying doses of heparin, a blood thinner, to prevent or reduce the formation of blood clots.

The ACTIV-4 convalescent protocol(link is external) will investigate the effectiveness and safety of anticoagulants and/or antiplatelets administered to patients who have been discharged from the hospital or are convalescing in reducing thrombotic complications such as heart attack, stroke, blood clots in major veins and arteries, deep vein and pulmonary thrombosis, and death. Researchers will assess if patients develop these complications within 45 days of being hospitalized for moderate and severe COVID-19.


(ACTIV-5
Big Effect Trial)

The ACTIV-5 master protocol(link is external) is designed to conduct a series of randomized, double-blind, placebo-controlled Phase 2 trials using common assessments and endpoints. Trials using this protocol will enroll hospitalized adults with COVID-19 to evaluate whether certain approved therapies or investigational drugs in late-stage clinical development show promise against COVID-19. Compounds that do not demonstrate efficacy based in interim evaluations will be dropped, while those that demonstrate efficacy will move forward to Phase 3 trials.


Order Of Alpha

I went behind enemy lines on this one.